Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DX30BA
|
|||
| Drug Name |
IBI318
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Phase 1 | [1] | |
| Company |
Innovent Biologics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | Inhibitor | [2] |
| Programmed cell death protein 1 (PD-1) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Reactome | PD-1 signaling | |||
| WikiPathways | T-Cell Receptor and Co-stimulatory Signaling | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04777084) The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Innovent. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.